Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America News Network.
Press releases published on May 15, 2025
ビットゲットウォレット (Bitget Wallet)、コンセンサス・トロント (Consensus Toronto) に参加して革新と成長を披露
GlobeNewswire
·
May 15, 2025
トロント発, May 16, 2025 (GLOBE NEWSWIRE) -- Web3の非管理型ウォレットの大手であるビットゲットウォレットは、Web3で最も期待されているイベントの1つであり、2025年5月14～16日に開催されるコンセンサス・トロントに参加する。 Web3が成熟する中でビットゲットウォレットがスポットライトを浴び、クロスチェーン相互運用性、スマート契約セキュリティ、ユーザー第一の設計における最新の進歩をアピールする。 …
Bitget Wallet Menyertai Consensus Toronto untuk Memperlihatkan Inovasi dan Pertumbuhan
GlobeNewswire
·
May 15, 2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Bitget Wallet, dompet Web3 tanpa jagaan yang terkemuka, akan menyertai Consensus Toronto, salah satu acara Web3 yang paling dinanti-nantikan, yang berlangsung dari 14 Mei hingga 16 Mei 2025. Seiring dengan …
Bitget Wallet 亮相 Consensus Toronto 大会，精彩呈现其创新成果与蓬勃增长
GlobeNewswire
·
May 15, 2025
多伦多, May 16, 2025 (GLOBE NEWSWIRE) -- 作为行业领先的非托管型 Web3 钱包，Bitget Wallet 将亮相备受瞩目的 Web3 盛会——Consensus Toronto。该大会定于 2025 年 5 月 14 日至 16 日举行。 随着 Web3 生态日益成熟，Bitget Wallet 将在此次大会上重点展示其在跨链互操作性、智能合约安全性和以用户为本的设计方面取得的最新成果。 此次亮相紧随 Bitget Wallet 推出 Shop with Crypto …
Bitget Wallet 參加多倫多 Consensus 大會，展現創新與發展
GlobeNewswire
·
May 15, 2025
多倫多, May 16, 2025 (GLOBE NEWSWIRE) -- Bitget Wallet 是世界領先的非託管 Web3 錢包，將參加多倫多 Consensus 大會，這是 Web3 界最受期待的活動之一，將於 2025 年 5 月 14 日至 5 月 16 日間舉行。 隨着 Web3的發展日趨成熟，Bitget Wallet 成為鎂光燈下的焦點，強調其跨鏈互通性、智能合約安全性及用戶導向設計的最新進展。 在此次亮相之前，Bitget Wallet 已推出了 Shop with Crypto …
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
GlobeNewswire
·
May 15, 2025
Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to December 2043 Ameluz PDT offers the potential for effective treatment of moderate to severe acne without the side effects associated …
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
GlobeNewswire
·
May 15, 2025
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. …
Silo Pharma Announces Pricing of $2 Million Public Offering
GlobeNewswire
·
May 15, 2025
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public …
High Grade at Globex’s Carp Fluorspar Property, Nevada
GlobeNewswire
·
May 15, 2025
ROUYN-NORANDA, Quebec, May 15, 2025 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang …
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
GlobeNewswire
·
May 15, 2025
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) …
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 15, 2025
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 …
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
GlobeNewswire
·
May 15, 2025
WARSAW, Poland, May 15, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and …
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GlobeNewswire
·
May 15, 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) …
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC …
Reflect Scientific Advances Market Presence by Transitioning from OTCQB to OTCIQ
GlobeNewswire
·
May 15, 2025
OREM, Utah, May 15, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of innovative cryogenic technologies for the life sciences and biotech industries, today announced that it is actively transitioning from the OTCQB Venture …
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
·
May 15, 2025
In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial …
Nuvini Group Completes Acquisition of B2B SaaS Platform Munddi
GlobeNewswire
·
May 15, 2025
~ Successfully Marks the First of Four Anticipated Acquisitions in 2025 ~ ~ Creates New Synergies to Drive Revenue Growth and Enhance NVNI’s Ecosystem of B2B SaaS Solutions across Latin America ~ NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Nuvini Group …
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 15, 2025
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic …
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
·
May 15, 2025
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May …